NEW YORK (GenomeWeb News) – Empire Genomics said today that it has acquired the exclusive license to a genomic biomarker from Emory University for the development of a molecular diagnostic test for determining which therapies may be most suitable for specific patients with multiple myeloma.

A phase II biomarker-driven clinical trial is being conducted using the technology to validate its ability to predict outcomes of new generations of drugs for the blood cell cancer, Empire Genomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.